11 Jan 2019 Research

Myelofibrosis: Finding new ways to treat patients

Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.

Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.

Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.

The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.

Related posts

University of Southampton’s Dr Giorgia Chiodin Wins Olive Boles Innovation Award

7 November 2024

University of Southampton’s Dr Giorgia Chiodin Wins Olive Boles Innovation Award

Dr Giorgia Chiodin from the University of Southampton has been awarded the prestigious Olive Boles Innovation Award for 2024. Awarded annually to a Leukaemia UK John Goldman Fellow, this award…

One Cancer Voice 10-Year Cancer Plan Consensus Statement

30 March 2022

One Cancer Voice 10-Year Cancer Plan Consensus Statement

We have joined with 53 cancer charities to speak with One Cancer Voice and publish 10 tests that the Government’s new 10-year Cancer Plan must meet if it is to be successful.

Leukaemia UK research paves the way for personalised lymphoma treatment

19 June 2023

Leukaemia UK research paves the way for personalised lymphoma treatment

Despite promising trials, standard treatment for diffuse large B-cell lymphoma (DLBCL) hasn’t changed in a decade. New treatment strategies for this type of blood cancer are urgently needed. Could the…

Leukaemia UK appoints Ian McCafferty CBE as their new Chair of Trustees to support new strategy to stop leukaemia devastating lives

7 November 2022

Leukaemia UK appoints Ian McCafferty CBE as their new Chair of Trustees to support new strategy to stop leukaemia devastating lives

Ian McCafferty CBE will take up the role in January 2023, from current Chair of Trustees, Chris Corbin OBE, and will lead the charity as it continues to grow. Chris…